Patents Assigned to DESIGNED CELLS CO.,LTD.
  • Patent number: 11998571
    Abstract: Disclosed herein is a pharmaceutical composition comprising at least one selected from the group consisting of a stem cell-conditioned medium and an exosome isolated therefrom as an active ingredient for prevention or treatment of an ocular disease. Containing exosomes, growth factors and neurotrophic factors at high levels and functioning to: promote retinal cell proliferation and wound recovery; protect retinal cells against oxidative stress or hypoxia; lower the increased intraocular pressure and restore the atrophy of the retinal layer and the retinal ganglion cell layer to normal levels in the glaucoma animal model; and have a protective effect on retinal ganglion cells and nerve cells, the stem cell-conditioned medium according to the present disclosure can find advantageous applications in the therapy of an ocular disease.
    Type: Grant
    Filed: October 14, 2022
    Date of Patent: June 4, 2024
    Assignee: DESIGNED CELLS CO., LTD.
    Inventors: Yun Bae Kim, Ehn Kyoung Choi, Tae Myoung Kim
  • Publication number: 20230134557
    Abstract: Disclosed herein is a pharmaceutical composition comprising at least one selected from the group consisting of a stem cell-conditioned medium and an exosome isolated therefrom as an active ingredient for prevention or treatment of an ocular disease. Containing exosomes, growth factors and neurotrophic factors at high levels and functioning to: promote retinal cell proliferation and wound recovery; protect retinal cells against oxidative stress or hypoxia; lower the increased intraocular pressure and restore the atrophy of the retinal layer and the retinal ganglion cell layer to normal levels in the glaucoma animal model; and have a protective effect on retinal ganglion cells and nerve cells, the stem cell-conditioned medium according to the present disclosure can find advantageous applications in the therapy of an ocular disease.
    Type: Application
    Filed: October 14, 2022
    Publication date: May 4, 2023
    Applicant: DESIGNED CELLS CO.,LTD.
    Inventors: Yun Bae KIM, Ehn Kyoung CHOI, Tae Myoung KIM
  • Publication number: 20230096790
    Abstract: Disclosed herein is a pharmaceutical composition containing a neprilysin-overexpressing stem cell, a conditioned medium thereof, and an exosome isolated therefrom as an active ingredient for prevention or treatment of cognitive impairment. Having the functions of protecting nerve cells, inhibiting the accumulation of amyloid beta, known as a cause of cognitive impairment-related disease in animal models, increasing an expression level of acetyl choline, and improving cognitive functions in animal models, the neprilysin-overexpressing stem cells, the conditioned medium thereof, or the exosomes isolated therefrom according to the present disclosure can find advantageous applications in treating cognitive impairment.
    Type: Application
    Filed: September 30, 2022
    Publication date: March 30, 2023
    Applicant: DESIGNED CELLS CO.,LTD.
    Inventors: Yun Bae Kim, Ehn Kyoung Choi, Tae Myoung Kim